Profile data is unavailable for this security.
About the company
Xvivo Perfusion AB is a Sweden-based medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation. The Company operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Company’s product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The Company markets its products in Europe, Asia, Middle East, and North & South America.
- Revenue in SEK (TTM)812.17m
- Net income in SEK25.16m
- Incorporated1998
- Employees198.00
- LocationXvivo Perfusion ABGemenskapens gata 9MOELNDAL 431 53SwedenSWE
- Phone+46 317882150
- Fax+46 317882169
- Websitehttps://www.xvivogroup.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CellaVision AB | 758.97m | 153.08m | 3.62bn | 236.00 | 23.65 | 4.08 | 18.82 | 4.77 | 6.42 | 6.42 | 31.82 | 37.21 | 0.7201 | 2.02 | 6.80 | -- | 14.52 | 14.71 | 16.22 | 16.96 | 68.50 | 68.38 | 20.17 | 19.85 | 2.97 | 25.88 | 0.0281 | 41.97 | 4.94 | 9.99 | 8.78 | 11.34 | 20.76 | 29.67 |
| IVF Hartmann Holding AG | 1.87bn | 223.36m | 3.89bn | 309.00 | 17.42 | 2.28 | 13.68 | 2.08 | 7.92 | 7.92 | 66.39 | 60.57 | 0.8964 | 3.28 | 7.88 | 526,221.10 | 10.69 | 7.90 | 12.91 | 9.68 | 55.71 | 54.06 | 11.93 | 9.13 | 3.79 | -- | 0.0042 | 48.54 | 7.33 | 2.85 | 34.02 | 10.78 | -28.94 | 19.92 |
| Medistim ASA | 634.70m | 135.20m | 3.97bn | 154.00 | 29.27 | 9.95 | 24.74 | 6.25 | 7.79 | 7.79 | 36.56 | 22.91 | 1.25 | 0.7679 | 9.67 | 4,341,637.00 | 26.72 | 21.98 | 33.09 | 27.19 | 81.21 | 78.66 | 21.30 | 20.32 | 2.03 | -- | 0.0484 | 85.04 | 6.88 | 9.12 | 0.0087 | 8.11 | 12.53 | 16.89 |
| COLTENE Holding AG | 2.83bn | 168.11m | 4.02bn | 1.18k | 23.92 | 3.79 | 16.26 | 1.42 | 2.40 | 2.40 | 40.22 | 15.13 | 1.31 | 1.34 | 6.40 | 204,684.50 | 7.80 | 10.59 | 14.26 | 18.43 | 66.11 | 62.19 | 5.95 | 7.64 | 0.7043 | 7.62 | 0.3606 | 85.66 | 3.06 | -1.79 | 71.31 | 0.4306 | -15.45 | 10.76 |
| medmix AG | 5.50bn | -68.12m | 4.58bn | 2.67k | -- | 0.9096 | 8.01 | 0.833 | -0.1696 | -0.1696 | 11.60 | 10.39 | 0.4707 | 3.56 | 5.86 | 174,403.90 | -0.4927 | 1.27 | -0.6199 | 1.55 | 34.52 | 35.24 | -1.05 | 2.65 | 1.10 | 1.87 | 0.4268 | 140.79 | -0.5549 | 2.84 | -2,566.67 | -- | 6.02 | -- |
| Ion Beam Applications SA | 6.36bn | 181.38m | 4.97bn | 2.10k | 27.09 | 3.79 | 15.80 | 0.7806 | 0.5677 | 0.5677 | 20.17 | 4.06 | 0.9756 | 2.73 | 3.28 | 281,693.60 | 2.78 | 1.50 | 12.03 | 4.64 | 31.21 | 34.39 | 2.85 | 2.15 | 0.6209 | 7.41 | 0.3631 | 70.81 | 6.75 | 12.01 | 201.57 | 3.99 | 7.69 | 25.86 |
| Revenio Group Oyj | 1.17bn | 185.61m | 5.29bn | 247.00 | 28.44 | 4.31 | 22.76 | 4.52 | 0.654 | 0.654 | 4.12 | 4.31 | 0.7515 | 3.05 | 7.26 | 444,129.60 | 11.92 | 14.00 | 14.23 | 17.40 | 70.92 | 70.95 | 15.86 | 19.38 | 1.63 | 9.66 | 0.0969 | -- | 5.97 | 12.43 | -5.93 | 5.42 | 22.19 | -- |
| Lumibird SA | 2.30bn | 114.43m | 5.39bn | 1.07k | 47.12 | 2.53 | 16.61 | 2.34 | 0.4775 | 0.4775 | 9.61 | 8.90 | 0.5077 | 0.9593 | 4.42 | 202,198.50 | 2.52 | 2.51 | 3.11 | 3.17 | 63.89 | 61.89 | 4.97 | 4.90 | 1.64 | 3.16 | 0.4583 | 0.00 | 1.75 | 13.34 | -20.08 | -8.38 | 15.27 | -- |
| Advanced Medical Solutions Group plc | 2.68bn | 111.09m | 5.74bn | 1.50k | 51.45 | 1.84 | 15.50 | 2.14 | 0.0417 | 0.0417 | 1.01 | 1.17 | 0.5758 | 2.09 | 5.57 | 137,690.00 | 2.38 | 5.09 | 2.63 | 5.52 | 52.19 | 55.06 | 4.14 | 11.15 | 1.55 | 3.88 | 0.2428 | 33.47 | 40.66 | 11.64 | -55.35 | -17.81 | 8.36 | 10.90 |
| RaySearch Laboratories AB (publ) | 1.34bn | 227.77m | 5.90bn | 458.00 | 28.82 | 6.67 | 11.38 | 4.39 | 6.65 | 6.65 | 39.25 | 28.74 | 0.6584 | 6.25 | 2.93 | 2,935,074.00 | 11.16 | 5.26 | 16.21 | 7.77 | 92.42 | 91.01 | 16.94 | 9.70 | 1.66 | 64.92 | 0.2861 | 52.38 | 12.77 | 15.58 | 11.93 | -- | 0.2213 | -- |
| Xvivo Perfusion AB | 812.17m | 25.16m | 5.91bn | 198.00 | 235.33 | 2.79 | 61.93 | 7.27 | 0.7968 | 0.7968 | 25.76 | 67.10 | 0.34 | 0.8939 | 6.13 | 4,101,844.00 | 1.05 | 3.28 | 1.12 | 3.52 | 73.81 | 73.86 | 3.10 | 10.87 | 3.68 | 1.83 | 0.0557 | 0.00 | -1.25 | 35.19 | -85.39 | -- | -- | -- |
| Gerresheimer AG | 24.00bn | 249.09m | 6.25bn | 13.54k | 25.07 | 0.4176 | 2.10 | 0.2602 | 0.676 | 0.676 | 65.15 | 40.59 | 0.5455 | 3.73 | 7.85 | 185,328.90 | 0.6341 | 3.30 | 0.8716 | 4.68 | 26.89 | 30.04 | 1.16 | 5.84 | 0.5214 | 2.08 | 0.6022 | 41.29 | 2.28 | 7.90 | -5.52 | 6.32 | 17.58 | -49.35 |
| Synektik SA | 1.78bn | 341.25m | 6.46bn | 203.00 | 18.94 | 9.90 | 16.68 | 3.62 | 15.84 | 12.20 | 82.79 | 30.29 | 1.30 | 6.46 | 5.73 | -- | 24.78 | 20.11 | 45.33 | 32.67 | 36.50 | 31.40 | 19.13 | 13.60 | 1.22 | 111.98 | 0.1114 | -- | 9.16 | 40.29 | 51.58 | 70.02 | 28.82 | -- |
| Arjo AB (publ) | 11.00bn | 334.00m | 6.88bn | 6.94k | 22.07 | 0.9884 | 4.82 | 0.6252 | 1.23 | 1.23 | 40.39 | 27.38 | 0.704 | 4.92 | 6.22 | 1,584,702.00 | 2.14 | 3.26 | 2.91 | 4.80 | 42.59 | 43.42 | 3.04 | 4.78 | 0.8494 | 3.99 | 0.4179 | 48.74 | -2.59 | 3.92 | -32.93 | -8.68 | -- | 2.25 |
| GVS SpA | 4.51bn | 243.91m | 8.07bn | 4.23k | 30.24 | 1.75 | 11.12 | 1.79 | 0.1323 | 0.1323 | 2.35 | 2.28 | 0.475 | 2.02 | 7.01 | 99,768.77 | 2.57 | 6.01 | 3.33 | 8.53 | 56.11 | 57.98 | 5.41 | 11.16 | 0.7567 | 2.40 | 0.4234 | -- | 0.8959 | 13.51 | 144.52 | 0.1729 | 23.38 | -- |
| Paul Hartmann AG | 25.88bn | 869.45m | 8.23bn | 10.09k | 9.41 | 0.6544 | 4.01 | 0.318 | 22.95 | 22.95 | 682.93 | 330.05 | 1.16 | 1.97 | 5.54 | 240,745.70 | 4.12 | 4.21 | 5.45 | 5.79 | 59.56 | 57.30 | 3.56 | 3.35 | 1.11 | 14.11 | 0.2465 | 37.95 | 2.32 | 1.95 | 281.58 | 13.23 | 10.08 | 2.71 |
Data as of Mar 02 2026. Currency figures normalised to Xvivo Perfusion AB's reporting currency: Swedish Krona SEK
28.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 28 Apr 2025 | 2.81m | 8.92% |
| Handelsbanken Fonder ABas of 31 Jan 2026 | 1.52m | 4.84% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 945.32k | 3.00% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2025 | 875.63k | 2.78% |
| Swedbank Robur Fonder ABas of 30 Jan 2026 | 632.22k | 2.01% |
| Andra AP-fondenas of 28 Apr 2025 | 586.17k | 1.86% |
| Premier Fund Managers Ltd.as of 28 Feb 2025 | 450.21k | 1.43% |
| Deka Investment GmbHas of 30 Jun 2025 | 377.18k | 1.20% |
| F�rsta AP-fondenas of 28 Apr 2025 | 330.00k | 1.05% |
| SEB Funds ABas of 30 Jan 2026 | 312.31k | 0.99% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
